Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evolving Therapeutic Landscape in Non-Muscle-Invasive Bladder Cancer (NMIBC).

Oncology·2026
Same author

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same author

PROTEUS: A Practice-changing Trial, but Are We Ready to Embrace Perioperative Apalutamide for All High-risk Patients?

European urology oncology·2026
Same author

Neurometabolic Signatures of Alexithymia and Visuospatial Abilities in Parkinson's Disease: An Exploratory <sup>1</sup>H-MRS Study of the Substantia Nigra and Globus Pallidus.

Journal of clinical medicine·2026
Same author

Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).

BMC cancer·2026
Same author

Tilting the balance toward motor symptoms: Determinants of caregiver burden in late-stage Parkinson's disease.

IBRO neuroscience reports·2026

Related Experiment Video

Updated: Jun 12, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

An evolving role for immunotherapy in metastatic RCC

Riccardo Autorino, Giuseppe Di Lorenzo

    Nature Reviews. Urology
    |June 11, 2010
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
    11:27

    Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

    Published on: April 29, 2014

    Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
    08:06

    Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

    Published on: November 26, 2010

    Related Experiment Videos

    Last Updated: Jun 12, 2026

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
    06:38

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

    Published on: April 12, 2017

    Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
    11:27

    Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

    Published on: April 29, 2014

    Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
    08:06

    Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

    Published on: November 26, 2010